Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Ferris Bueller once said: “Life moves pretty fast. If you don’t stop and look around once in a while, you could miss it.”
Timmerman Report started two years ago. It’s time to thank subscribers, and throw a couple free community parties – one in the East, one in the West.
The Boston party will be on Apr. 13, and Seattle’s will be May 9. Check them out:
Celebrate the TR 2nd Anniversary party 4-6 pm Apr. 13 at Alnylam Pharmaceuticals! Network with Boston biotech community peers, and join TR founder Luke Timmerman for this free event. Phil Sharp, Institute Professor at MIT, will discuss Timmerman’s biography of automated DNA sequencing pioneer Lee Hood. Abbie Celniker, partner at Third Rock Ventures and chair of MassBio, will discuss day-to-day constructive things that are happening to advance women in biotech leadership. Signed copies of Timmerman’s new book, “Hood: Trailblazer of the Genomics Age,” which Forbes calls a “must read,” will be available for purchase. Plus, enjoy some beautiful photos from Aconcagua, the highest peak in South America. The event is free, and subscribers are welcome to bring friends, but please RSVP here for Boston on Apr. 13.
TR Boston launch party, April 2015. Photo by Kayana Szymczak.
Come celebrate the TR’s 2nd Anniversary on May 9 at Adaptive Biotechnologies! Network with Seattle biotech community peers, and join TR founder Luke Timmerman for this free event. Special guests Charlotte Hubbert, a partner with Gates Foundation Venture Capital, and Thong Le, CEO of Accelerator, will discuss the opportunities they see in the investment landscape. Executives of some of Seattle’s most interesting biotech startups will give quick 3-minute updates on what they’re doing. Signed copies of Timmerman’s new book, “Hood: Trailblazer of the Genomics Age,” which Forbes calls a “must read,” will be available for purchase. See some beautiful photos from Aconcagua, the highest peak in South America. The event is free, and subscribers are welcome to bring friends, but please RSVP here for Seattle on May 9.
TR Seattle launch party. March 2015. Photo by Robert Wade.
The East and West Coast anniversary parties are a tradition at TR. Helping people form connections in the community is one of the ways I can thank people for supporting my mission for quality independent biotech journalism.
I look forward to seeing you there and hearing about your latest adventures in biotech.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
